Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 28, 2017 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics President and CEO Issues Letter to Stockholders Highlighting Key Accomplishments and Outlines Milestones for 2018

SEATTLE, Dec. 28, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) today announced it has issued the following letter by Dr. Steven C. Quay, President and CEO, to Atossa stockholders: ...
December 21, 2017 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Appoints Carl Novina, MD, PhD as Scientific Advisor

SEATTLE, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
December 20, 2017 09:15 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Pricing of $1.4 Million Registered Direct Offering

SEATTLE, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
November 14, 2017 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Third Quarter 2017 Financial Results And Provides Company Update

SEATTLE, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
November 06, 2017 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Applauds Newly-Introduced Federal Legislation Requiring That Breast Density Be Reported To Physicians and Patients

SEATTLE, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other...
October 30, 2017 12:30 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Closing of $5.5 Million Common Stock Public Offering and Over-allotment Option

SEATTLE, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
October 26, 2017 09:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Pricing of $5.1 Million Public Offering of Common Stock

SEATTLE, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
October 25, 2017 18:25 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Proposed Public Offering of Common Stock

SEATTLE, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
October 25, 2017 09:45 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces Preliminary Results from Phase 1 Study of Oral Endoxifen

All Objectives Successfully Met Conference Call To Be Held Today at 10 am Eastern Time SEATTLE, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage...
October 23, 2017 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Oral Endoxifen Wednesday, October 25, 2017 at 10 am EDT

SEATTLE, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other...